Patent Grant
11504513
Drugs may be delivered to patients by a variety of methods including oral, intravenous, intramuscular, inhalation, topical, subcutaneous delivery or delivery directly or locally to the treatment site (e.g., intrathecally, intraspinally, intraarticularly, etc.). The method of delivery chosen depends, among other things, upon the condition being treated, desired therapeutic concentration of the drug to be achieved in the patient and the duration of drug concentration that must be maintained.
Recently, drug depots have been developed which allow a drug to be introduced or administered to sites beneath the skin of a patient so that the drug is slowly released over a long period of time. Such drug depots allow the drug to be released from the depot in a relatively uniform dose over weeks, months or even years. This method of administering drugs is becoming especially important and popular in modulating the immune, inflammation and/or pain responses in treatment of chronic conditions including rheumatoid arthritis, osteoarthritis, sciatica, carpal tunnel syndrome, lower back pain, lower extremity pain, upper extremity pain, cancer, tissue pain and pain associated with injury or repair of cervical, thoracic, and/or lumbar vertebrae or intervertebral discs, rotator cuff, articular joint. TMJ, tendons, ligaments, muscles, and the like.
Previously, drug depots and other types of implants have been inserted into the treatment site beneath the skin by use of a trocar device, which is a two-piece device that includes a cannula and an obdurator. The trocar device requires an incision to be made through the skin at the site of implant of the drug depot using a separate instrument (e.g., scalpel). A cannula and obdurator are inserted together through the skin at the incision site. Next, the obdurator is withdrawn, leaving the cannula in place as a guide for inserting the drug depot. The drug depot is inserted through the cannula, and the obdurator is used to push the implant to the end of the cannula. The cannula and obdurator are then withdrawn completely, leaving the implant in place beneath the skin.
Typically, trocar devices are used to implant drug depots subcutaneously over a large area (e.g., 2-2.5 inches), with a typical drug depot in the order of 1½ inches long. Thus, the trocar device is not suitable for many treatment sites because it lacks precision and may cause additional trauma to the tissue surrounding the site of implant.
Other drug delivery devices have been developed to simplify implanting the drug depots. These devices have a handle for one-handed implantation of the drug depot, a needle containing the drug depot to be implanted and a rod positioned within the needle for pushing the drug depot out of the needle. Once the needle containing the drug depot has been inserted at the site of implant, a spring loaded trigger on the handle is activated which causes the needle to be automatically withdrawn by a spring leaving the implanted drug depot in place. Unfortunately, it is not possible to control the motion of the needle in these devices because the needle will automatically retract upon activation of the trigger. The complex spring loaded propelling system and trigger of these devices increase the chances that the device will jam and fail to eject the drug depot when required.
Conventional needle and syringe devices have been used to implant a drug depot to sites such as, for example, the epidural space. These devices typically utilize a syringe preloaded with the drug depot and an epidural needle. The needle is inserted through the skin, supraspinus ligament, intraspinus ligament, ligamentum flavum and then into the epidural space. The drug depot is delivered through the needle to the epidural space using the syringe plunger. Conventional needle and syringe devices often do not easily allow controlled and precision implant of the drug depot. If multiple drug depot implants are needed, these conventional needle and syringe devices often do not allow accurate placement of the implant in a manner so that one drug depot does not substantially interfere with the dissolution of the other.
In certain methods of drug depot implantation, the drug depots are secured in the drug cartridge by use of a bulking agent. The bulking agent may be added to the drug depot to ensure the drug depot is secure within the chamber, such that the drug depot is released when a plunger is engaged to dislodge the drug depot from the cartridge. The bulking agent is sometimes added to the drug chamber before the drug depot is added to the chamber. Other times the drug depot is added to the drug chamber first and then the drug depot is added to the chamber. Use of a bulking agent to retain the drug depot in a drug cartridge requires additional steps and is time consuming. Thus, a drug delivery device which reduces a need for use of bulking agents is needed.
New drug delivery devices are needed, which can easily allow accurate and precise implantation of a drug depot with minimal physical and psychological trauma to a patient. When implanting several drug depots, a drug delivery device is needed that accurately and precisely allows placement of the drug depot in a manner such that one depot does not substantially interfere with the dissolution of the others.
New drug delivery devices, which can easily allow accurate and precise implantation of a drug depot with minimal physical and psychological trauma to a patient are provided.
Briefly stated, provided are embodiments of a device, a kit and method for delivering a drug depot are disclosed. The device comprises a housing including a lower body, an upper body, a ring member, and a drug cartridge. The lower body defines a lower body channel. The upper body defines an upper body channel. The drug cartridge defines a depot channel. The ring member is disposed extending upward from an annular step surface of the lower body toward a housing upper end. The ring member includes indicia indicating a characteristic of one or more drug depots in the drug cartridge. A plunger has a push rod for-expelling the drug depot through the cannula to a site in the patient. A kit comprises the above components. A method includes assembling the components including selecting a ring member having indicia corresponding to one or more drug depots in the drug cartridge.
The present disclosure provides a drug delivery device, in various embodiments, for delivering a drug depot to a site beneath the skin of patient via a cannula having a proximal end and a distal end, the proximal end of the cannula having an opening to receive the drug depot, the distal end of the cannula being configured for insertion to the site beneath the skin of the patient and having an opening for passage of the drug depot. The device comprises a housing including a lower body, an upper body, a ring member, and a drug cartridge, the housing having a housing upper end, a housing lower end and a longitudinal direction defined as extending from the housing upper end to the housing lower end. The lower body has a lower body bottom end, a lower body upper end, and an annular step surface extending inward from an outer periphery of the lower body, and the lower body defines a lower body channel extending in the longitudinal direction. The lower body channel has a lower body channel first end open to the lower body upper end and a lower body channel second end open to the lower body bottom end. The lower body bottom end has a coupling configuration for engaging the proximal end of the cannula. The upper body has an upper body top end and an upper body bottom end, the upper body defines an upper body channel open to the upper body top end, and the upper body is connected to the lower body. The drug cartridge defines a depot channel aligned with the lower body channel and the upper body channel, and configured to slidably accept the drug depot. The ring member has a ring top end and a ring bottom end, and the ring member is disposed so as to extend upward from the annular step surface toward the housing upper end and so as to contact at least one of the upper body and the lower body. A plunger has a push rod slidably receivable in the upper body channel, the depot channel, the lower body channel, and the cannula. The push rod has a push rod end to contact the drug depot when disposed in the drug cartridge and, upon application of force, expel the drug depot through the cannula to the site beneath the skin of the patient.
In one embodiment of the present disclosure, there is provided a kit for preparing a device for delivering a drug depot to a site beneath the skin of a patient in conjunction with a cannula having a proximal end and a distal end, the proximal end of the cannula having an opening to receive the drug depot, the distal end of the cannula being configured for insertion to the site beneath the skin of the patient and having an opening for passage of the drug depot. The kit comprises components for a housing including a lower body, an upper body, a ring member, and a drug cartridge, the housing when assembled having a housing upper end, a housing lower end and a longitudinal direction defined as extending from the housing upper end to the housing lower end. The lower body has a lower body bottom end, a lower body upper end, and an annular step surface extending inward from an outer periphery of the lower body, and the lower body defines a lower body channel extending in the longitudinal direction. The lower body channel has a lower body channel first end open to the lower-body upper end and a lower body channel second end open to the lower body bottom end. The lower body bottom end has a coupling configuration for engaging the proximal end of the cannula. The upper body has an upper body top end and an upper body bottom end, the upper body defines an upper body channel open to the upper body top end, and the upper body is connectable by snap catches to the lower body. The drug cartridge defines a depot channel alignable with the lower-body channel and the upper body channel when installed in the lower body, and the depot channel is configured to slidably accept the drug depot. The ring member has a ring top end and a ring bottom end, and the ring member is disposable so as to extend upward from the annular step surface toward the housing upper end and so at to contact at least one of the upper body and the lower-body when assembled with the upper body and the lower body. A plunger has a push rod slidably receivable in the upper body channel, the depot channel, the lower body channel, and the cannula, and the push rod has a push rod end to contact the drug depot when, disposed in the drug cartridge and, upon application of force, expel the drug depot through the cannula to the site beneath the skin of the patient.
In another embodiment, a method of preparing a device to deliver a drug depot to a target site beneath the skin is provided. The method comprises providing the kit described above including more than one drug depots and more than one ring member, each having indicia. Selecting one or more of the drug depots. Selecting one of the rings members having indicia corresponding to the selected one of more of the drug depots. Sliding the selected ring member onto one of the upper body or the lower body. Installing the upper body and the drug cartridge to the lower body including engaging the upper body to the lower body using the snap catches. Loading the drug cartridge with the selected one or more drug depots and engaging the cannula with the lower body.
In one embodiment, there is a device for delivering a drug depot to a site beneath the skin of patient via a cannula having a proximal end and a distal, end, the proximal end of the cannula having an opening to receive the drug depot the distal end of the cannula being configured for insertion to the site beneath the akin of the patient and having an opening for passage of the drug depot, the device comprising: a housing having a top housing end, and a bottom housing end, said housing further defining a housing channel having a housing channel first open end open to said top housing end and a second housing channel open end open to said bottom housing end: a drug cartridge defining a depot channel aligned with said housing channel and configured to slidably accept the drug depot, said drug cartridge having at least a first occluding device configured to at least partially occlude said depot channel at a first occluding position such that the drug depot cannot pass through said depot channel at said first occluding position without force, greater than that of gravity, applied to the drug depot sufficient to deflect said first occluding device an amount permitting passage of the drug depot past said first occluding device; said bottom housing end of said housing has a coupling configuration for engaging the proximal end of the cannula; and a plunger having a push rod slidably receivable in said housing channel and the cannula and having a push rod end to contact the drug depot when disposed in said drug cartridge and, upon application of force, expel the drug depot through said first occluding device and the cannula to the site beneath the skin of the patient.
In another embodiment, there is a kit for delivering a drug depot to a site beneath the skin of a patient in conjunction with a cannula having a proximal end and a distal end, the proximal end of the cannula having an opening to receive the drug depot, the distal end of the cannula being configured for insertion to the site beneath the skin of the patient and having an opening for passage of the drug depot, the kit comprising: a housing having a top housing end, and a bottom housing end, said housing further defining a housing channel having a housing channel first open end open to said top housing end and a second housing channel open end open to said bottom housing end; a drug cartridge defining a depot channel disposed to be aligned with said housing channel and configured to slidably accept the drug depot, said drug cartridge having at least a first, occluding device configured to at least partially occlude said depot channel at a first occluding position such that the drug depot cannot pass through said depot channel at said first occluding position without force, greater than that of gravity, applied to the drug depot sufficient to deflect said first occluding device an amount permitting passage of the drug depot past said first occluding device; said bottom housing end of said housing having a coupling configuration for engaging the proximal end of the cannula; and a plunger having a push rod slidably receivable in said housing channel and the cannula and having a push rod end to contact the drug depot when disposed in said drug cartridge and, upon application of force, expel the drug depot through either of the first occluding device and the cannula to the site beneath the skin of the patient.
In another embodiment, there is a device for delivering a drug depot to a site beneath the skin of patient via a cannula having a proximal end and a distal end, the proximal end of the cannula having an opening to receive the drug depot, the distal end of the cannula being configured for insertion to the site beneath the skin of the patient and having an opening for passage of the drug depot, the device comprising: a housing body having housing body top end and a housing body bottom end, said housing body further defining a housing body channel having a housing body channel first open end open to said housing body top end and a second housing channel open end open to said housing body bottom end; a housing cap member having a housing cap top end, and a housing, cap bottom end, said housing cap member further defining a housing cap channel having a housing cap channel first open end open to said housing cap top end and a second housing cap channel open end open to said housing cap bottom end; said housing cap member being connected to, said housing body a drug cartridge, defining a depot channel aligned with said housing cap channel and said housing body channel, said drug cartridge being configured to slidably accept the drug depot, said drug cartridge having at least a first occluding device configured to at least partially occlude said depot channel at a first occluding position such that the drug depot cannot pass through said depot channel at said first occluding position without force, greater than that of gravity, applied to the drug depot sufficient to deflect said first occluding device an amount permitting passage of the drug depot past said first occluding device; said housing body bottom end having a coupling configuration for engaging the proximal end of the cannula; and a plunger having a push rod slidably receivable in said housing cap channel, said depot channel, and said housing body channel, said push rod having a push rod end to contact the drug depot when disposed in said drug cartridge and, upon application of force, expel the drug depot through said first occluding device and the cannula to the site beneath the skin of the patient.
In yet another embodiment, there is a method of delivering a drug depot to a target site beneath the skin, the method comprising: inserting a cannula at the target tissue site, the cannula having a proximal end and a distal end, the proximal end of the cannula having an opening to receive a drug pellet, the distal end of the cannula configured for insertion to the target site beneath the skin of the patient and having an opening for passage of the drug pellet; loading a drug delivery device with at least one drug depot, said drug delivery device comprising: a housing having a top housing end, and a bottom housing end, said housing further defining a housing channel having a housing channel, first open end open to said top housing end and a second housing channel open end open to said bottom housing end; a drug cartridge defining a depot channel which is loaded with said at least one drug depot, said depot channel being aligned with said housing channel and configured to slidably accept the drug depot, said drug cartridge having at least a first occluding device configured to at least partially occlude said depot channel at a first occluding position such that the drug depot cannot pass through said depot channel at said first occluding position without force, greater than that of gravity, applied to the drug depot sufficient to deflect said first occluding device an amount permitting passage of the drug depot past said first occluding device said bottom housing end of said housing has a coupling configuration for engaging the proximal end of the cannula; and a plunger having a push rod slidably receivable in said housing channel and the cannula and having a push rod end to contact the drug depot when disposed in said drug cartridge and, upon application of force, expel the drug depot through the first occluding, device and the cannula to the site beneath the skin of the patient attaching said drug delivery device to the proximal end of the cannula; and inserting said push rod of said plunger into said housing channel of said drug delivery device and applying force to expel, the drug depot through said first occluding device and the cannula to the site beneath the skin of the patient.
Additional features and advantages of various embodiments will be set forth in part in the description that follows, and in part will be apparent from the description, or may be learned by practice of various embodiments. The objectives and other advantages of various embodiments will be realized and attained by means of the elements and combinations particularly-pointed out in the description and appended claims.
In part, other aspects, features, benefits and advantages of the embodiments will be apparent with regard to the following description, appended claims and accompanying drawings where:
It is to be understood that the figures are not drawn to scale. Further, the relation between objects in a figure may not be to scale, and may in fact have a reverse relationship as to size. The figures are intended to bring understanding and clarity to the structure of each object shown, and thus, some features may be exaggerated in order to illustrate a specific feature of a structure.
For the purposes of this specification and appended claims, unless otherwise indicated, all numbers expressing quantities of ingredients, percentages or proportions of materials, reaction conditions, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the embodiments of the present disclosure. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. Moreover, all ranges disclosed herein are to be understood to encompass any and all subranges subsumed therein. For example, a range of “1 to 10” includes any and all subranges between (and including) the minimum value of 1 and the maximum value of 10, that is, any and all subranges having a minimum value of equal to or greater than 1 and a maximum value of equal to or less than 10, e.g., 5.5 to 10.
It is noted that, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the,” include plural referents unless expressly and unequivocally limited, to one referent. Thus, for example, reference to “a drug-depot” includes one, two, three or more drug depots.
Reference will now be made in detail to various embodiments of the present disclosure, examples of which are illustrated in the accompanying drawings. While the embodiments of the present disclosure will be described, in conjunction with the illustrated embodiments, it will be understood that they are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the invention as defined by the appended claims.
The headings below are not meant to limit the disclosure in any way: embodiments under any one heading may be used in conjunction with embodiments under any other heading.
New drug delivery devices, which can easily allow the accurate and precise implantation of multiple drug depots with minimal physical and psychological trauma to a patient are provided. In various embodiments the drug delivery device allows the user to dispense multiple drug depots, in sequence, to a site beneath the skin of the patient.
An optional feature of the drug delivery device of the present disclosure is that it allows the user to dispense multiple doses of the drug in sequence.
Another optional feature is that various embodiment include occluding devices that prevent drug depots from inadvertently being dislodged from the drug delivery device.
Still another feature optionally provided in various embodiments is a viewing aperture permitting visual confirmation of a number and type of drug depots after loading of the drug depots into the drug delivery device.
Yet another optional feature of various embodiments of the drug delivery device is a funnel body facilitating loading of small drug depots which are difficult to manually manipulate into small apertures.
A further optional feature of various embodiments of the drug delivery device is an indicia ring which includes either or both of alphanumeric labeling or color coding to facilitate selection of a drug delivery device containing the correct drug.
A further optional feature of various embodiments of the drug delivery device is a method wherein the drug cartridge is loaded with drug depots during assembly of the device.
A further optional feature of various embodiments of the drug delivery device is a method wherein the drug cartridge is breach loaded with drug depots after assembly of the device.
A further optional feature of various embodiments of the drug delivery device is a snap catch engagement of an upper body to a lower body so as to secure a ring member having indicia corresponding to drug depot in a drug cartridge of the device or to be breach loaded into the drug cartridge.
Referring to
The housing body 104 optionally defines, a viewing aperture 106 configured to allow viewing of a drug cartridge (discussed below) within the housing body 104 so as to confirm presence of drug depots. The viewing aperture 106 is sized to permit viewing of multiple drug depots loaded into the drug cartridge.
In various embodiments of the drug-delivery device the cannula 110 has a proximal end engaged to the housing via a coupling device which is optionally embodied as, inter alia, a luer lock, threading fitting, friction fit fitting, or another fitting mechanism allowing the cannula 110 to functionally couple to the housing 100 so as to permit passage of a drug depot through the cannula 110 via entry at the proximal end and exit at a distal id. In various embodiments, the cannula 110 is hollow having a sufficient diameter to allow passage of the drug depot and the push rod 124 that facilitates delivery of the drug to the designated site beneath the skin. The distal end of the cannula 110 is capable of insertion to a site beneath the skin. The size of the cannula is dictated by the procedure.
Referring to
The first drug cartridge 130 is inserted into a receiving channel 162 of the housing body 104 with the proximal and distal O-rings. 136 and 134, respectively disposed at proximal and distal ends of the cartridge tube 132 as shown in the cross-sectional view of
The funnel body 102 has a funnel bore 150 which has a funnel taper at the proximal end and transitions to a tubular configuration 151 opening at a distal end in alignment with the proximate O-ring 136. The funnel body 102 has a stepped configuration with a first step portion 154 and a second stepped portion 161 which respectively fit into a stepped recess of the housing body 140 comprising a first recess opening 152 and a second recess opening 161. The first step portion 154 has key ridges 156 (one visible in
The housing body 104 shown has an exemplary embodiment of the coupling device for connecting the cannula 110 comprising a nipple portion 174 defining a nipple channel 175 which is in alignment with the distal O-ring 134 so as to permit passage of the drug depots 140 therethrough and into the cannula 110 (shown in
The drug depots 140 are optionally loaded into the cartridge tube 130 during assembly of the first drug cartridge 13Q into the housing body 104 and prior to placement of the proximate O-ring 136 and closure with the housing 100 with the funnel body 102. Such an operation is carried out by first installing the distal O-ring 134 into a bottom of the receiving channel 162 followed by installing the cartridge tube 132 into the receiving channel 162 such that a bottom of the cartridge tube 132 contacts or is proximate to the distal O-ring 134. Next, one or more of the drug depots 140 are inserted into the cartridge tube 132 via the proximate end thereof. Following insertion of the drug depots 140, the proximate O-ring 136 is installed followed by press fitting of the funnel body 102. Alternatively, the drug depots 140 may be breach loaded into the first drug cartridge 130 after assembly of the housing 100 including installation of the first drug cartridge 130. Using breach loading the drug depots 140 are disposed into the funnel bore 150 so that they are guided into the tubular configuration 151 of the funnel bore 150 by the funnel taper. Once in the tubular configuration 151 the drug depots 140 fall to the proximate O-ring 136 which restricts further falling. The push rod 124 of the plunger 120 is then used to push the individual ones of the drug depots 140 through the aperture of the proximate O-ring 136, expanding the proximate O-ring 136 in the process, and into the cartridge tube 132 whereat the drug depots 140 are retained by the proximate and distal O-rings, 136 and 134, until use.
Administration of the drug depots 140 is effected by first engaging the cannula 110 via the coupling device of the housing body 104. As an example without limitation in the illustrated embodiment, a luer lock coupling is used which engages the internal thread 172 of the coupling bore. An indicator ridge 108 is optionally provided on the housing body 104 such that when proper coupling of the luer lock is made, a corresponding ridge on a luer lock portion of the cannula 110 aligns with the indicator ridge 108 of the housing body 104. Prior to disposing the drug depots 140 in the patient, the user visually confirms presence of a correct number and type of the drug depots. 140 via the viewing aperture 106 and the transparent body of the cartridge tube 132. Next, the cannula is inserted into the patient to place the tip of the cannula 110 at a desired location for disposition of the drug depots 140. Then the push rod 124 of the plunger 120 is inserted into the funnel bore 150 and on through the first drug cartridge 130, the housing body 104, and the cannula 110, so as to push the drug depots 140 out of the cannula 110 at the desired disposition location in the patient.
Referring now to
A second drug cartridge 180 is used in place of the first drug cartridge 130 and is inserted into a second receiving channel 162a of a second housing body 104. The second receiving channel 162a is rectangular in cross section while the first receiving channel 162 is circular. The second drug cartridge 180 comprises first and second plates, 182 and 184, respectively having first and second cantilever arms, 194 and 196, with corresponding ramped protrusions, 195 and 197, at distal ends thereof with proximate ends thereof acting as fixed cantilever mounts. The first and second plates, 182 and 184, each have a half channel, 190 and 192, extending from an end of a respective plate along a body of the respective plate and a corresponding one of the cantilever arms, 194 and 196, up to a corresponding one of the ramped protrusions. 195 and 197. Optionally, the first and second plates, 182 and 184, are formed identically to reduce manufacturing and assembly costs. The first and second plates, 182 and 184, each have bosses 186 and corresponding boss receiving holes 188. The first and second plates, 182 and 184, are fitted together as illustrated in
When the first and second plates, 182 and 184, are assembled together, the half channels. 190 and 192, align together and define a depot channel 199 for receipt of the drug depots 140 as shown in
Preferably, although not required, the first and second plates. 182 and 184, are formed of clear or transparent material to permit visual confirmation of the number and type of the drug depots 140 loaded in the second drug cartridge 180 via the viewing aperture 106. As in the case of the first drug cartridge 130, the drug depots 140 may be loaded into the second drug cartridge 180 either during assembly or post assembly by breach loading.
While in the illustrated embodiment of the second drug cartridge 180 the first and second plates. 182 and 184, are identical, this is not a requirement of the present disclosure. Alternatively, one of the plates may include both of the cantilever arms, 194 and 196, while another one of the plates defines a continuous half channel. Likewise, the bosses 186 and receiving holes 188, may be redistributed among the plates with all bosses or all boss receiving holes on one plate and with all receiving holes or all bosses on-another one of the plates. Other configurations of the plates may be effected which provide for the retention of the drug depots 140 such as providing an elastically biased occlusion of a depot channel by means of elastomeric buttons, coils springs, fuzz balls formed of plastic, elastic foam material, flexible fibers, or biased beveled end pins, which are merely examples of other retention devices and not considered limiting.
The drug depots 140 are optionally loaded into the second drug cartridge 180 during assembly of the second drug cartridge 180 and prior to placement of the second drug cartridge 180 into the housing body 104a and closure with the funnel body 102. Such an operation is carried out by placement of one or more of the drug depots into the half channel 192 of the second plate 184. Next, the first plate 182 is pressed into place over the second plate 184. Then, the assembled second drug cartridge 180 is installed into the receiving channel 162a and the funnel body 102 is pressed into place. Alternatively, the drug depots 140 may be breach loaded into the second drug-cartridge 180 after assembly of the housing 100 including installation of the second drug cartridge 180. Using breach loading the drug depots 140 are disposed into the funnel bore 150 so that they are guided into the tubular configuration 151 of the funnel bore 150 by the funnel taper. Once in the tubular configuration 151 the drug depots 140 fall into the second drug cartridge 180 up to a first of the ramped protrusions, 195 and 197, encountered. The push rod 124 of the plunger 120 is then used to push the drug depots 140 past the first of the ramped protrusions, 195 and 197, encountered, deflecting a corresponding one of the first and second cantilever arms. 194 and 196, in the process, to permit passage of the drug depot into the depot channel formed by the first and second half channels. 190 and 192, to a position between the first and second ramped protrusion. 1.95 and 197. The drug depots 140 are retained until use in the second drug cartridge 180 by the first and second ramped protrusions, 195 and 197, occluding the depot channel.
Administration of the drug depots 140 is effected by first engaging the cannula 110 via the coupling device of the housing body 104a and the cannula 110, as in the example of the first embodiment, a luer lock coupling is used which engages the internal thread 172 of the coupling bore. An indicator ridge 108 is provided on the housing body 104 such that when proper coupling of the luer lock is made, a corresponding ridge on a luer lock portion of the cannula 110 aligns with the indicator ridge of 108 of housing body. Prior to disposing the drug depots 140 in the patient, the user visually confirms presence of a correct number and type of the drug depots 140 via the viewing aperture 106 and the transparent body of the second drug cartridge 180. Next, the cannula 110 is inserted into the patient to place the tip of the cannula 110 at a desired location for disposition of the drug depots 140. Then the push rod 124 of the plunger 120 is inserted into the funnel bore 150 and on through the second drug cartridge 180, the housing body 104a, and the cannula 110, so as to push the drug depots 140 out of the cannula 110 at the desired disposition location in the patient.
Referring now to
In
As illustrated in
When the plunger 120 is fully inserted, the plunger knob 122 is adjacent the first ring member 210. Optional selection of different colors for the plunger knob 122 and the first ring member 210 provides contrast when the plunger 120 is fully inserted facilitating visual confirmation that the plunger 120 is fully inserted.
Referring to
Referring to
As shown in
Preferably, although not required, at least one. And more preferably both the first cartridge plate 200 and the second cartridge plate 202 are formed of clear or transparent material to permit visual confirmation of the number and type of the drug depots 140 loaded in the partially integrated drug cartridge via the viewing aperture 106. As in the case of the first and second drug cartridges, 130 and 180, the drug depots 140 may be loaded into the second drug cartridge 180 either during assembly or post assembly by breach loading.
Referring to
Referring to
The second funnel body 102b is secured in the third housing body 104b by means of the cantilever catch arms 220 and the catch hook protrusions 221 respectively engaging the stanchions 240 and the snap engagement apertures 242. Additionally, the second funnel body 102b has flanges 250 which seat on ends of the stanchions 240 in cooperation with the engagement of the cantilever catch arms 220 thereby securing the second funnel body. 102b in a longitudinal direction of the third housing body 104b. The first ring member 210 is secured in the longitudinal direction between a ledge 254 of the third housing body 104b and inclined faces 256 of the second funnel body 102b, which engage corresponding inclined faces 258 of the first ring member 210.
The drug depots 140 are optionally loaded into the partially integral drug cartridge during assembly of the partially integral drug cartridge 180 and prior to placement of the partially integral drug cartridge 180 into the housing body 104a and closure with the funnel body 102. Such an operation is carried out by placement of one or more of the drug depots into the half channel 192 of the second plate 184. Next, the first plate 182 is pressed into place over the second plate 184. Then, the assembled partially integral drug cartridge is installed into the housing body 104b and the funnel body 102b is pressed into place. Alternatively, the drug depots 140 may be breach loaded into the partially integral drug cartridge after assembly of the partially integral drug cartridge and installation thereof into the housing body 104b as shown in
Administration of the drug depots 140 is effected by first engaging the cannula 110 via the coupling device of the housing body 104b and the cannula 110, as in the example of the first embodiment, a luer lock coupling is used which engages the internal thread 172 of the coupling bore. An indicator ridge 108 is provided on the housing body 104 such that when proper coupling of the luer lock is made, a corresponding ridge on a luer lock portion of the cannula 110 aligns with the indicator ridge of 108 of housing body. Prior to disposing the drug depots 140 in the patient, the user visually confirms presence of a correct number and, type of the drug depots 140 via the viewing aperture 106 and the transparent, body of the partially integral drug cartridge. Next, the cannula 110 is inserted into the patient to place the tip of the cannula 110 at a desired location for disposition of the drug depots 140. Then the push rod 124 of the plunger 120 is inserted into the funnel bore 150 and on through the partially integral drug cartridge, the housing body 104b, and the cannula 110, so as to push the drug depots 140 out of the cannula 110 at the desired disposition location in the patient.
Referring to
The fourth housing body 104c has a stanchion ring 104c defining snap engagement apertures 242c instead of the stanchions 240 of the third housing body 104b. The second ring member 210c lacks the inclined faces 258 of the first ring member 210 and instead has a wider ring end surface 260. The fourth funnel body 102c lacks the inclined surface 256 of the third funnel body and instead has a funnel flange 262 which forms an annular end surface wider than that of the third funnel body 102b and an outer peripheral surface 266. The funnel flange 262 has a flange under-face 264 which secures the second ring member 210c in the longitudinal direction in conjunction with the ledge 254 of the fourth funnel body 102c. The outer peripheral surface 266 remains exposed after assembly of the drug delivery device as shown in
This embodiment has the funnel and cartridge plate in one piece, prongs 257 are reinforced and rib 255 extending about portions of the funnel reinforce the device. Referring to
The third cartridge plate 200d has second cantilever catch hook arms 206, at positions along longitudinal sides of the third cartridge plate 200d, which fit in notches 211 to engage second hook engaging protrusions 206d so as to affix the third cartridge plate 200d to the fourth cartridge plate 202d. The third cartridge plate 200d has' cantilever C-arms 208d extending from bases on an interior plate portion 213 so as to be deflectable relative the interior plate portion 213. The cantilever C-arms 208d have protrusion portions 207d configured to at least partially occlude a full depot channel 203-d of the fourth cartridge plate 202d at proximate and distal positions to prevent passage of the drug depots 140 without force being applied by the push rod 124. The protrusions 207d are flexible end when the drug depot engages them they allow passage of it past the protrusions on application of force from the plunger. As in the above embodiments, a force required to deflect the cantilever C-arms 208d an amount permitting passage of the drug depots 140 is not great enough to affect structural integrity of the drug depots 140. The full depot channel 203d has a depth at least equal to a diameter of the drug depots such that when the third cartridge plate 200d is engaged with the fourth cartridge plate 202d the drug depots 140 are contained in the full depot channel 203d by the interior plate portion 213. The interior plate portion 213 has bosses 216 configured to engage boss receiving apertures 217 in the fourth cartridge plate 202d so as to further-align the third and fourth cartridge plates, 200d and 202d, in addition to the second cantilever catch hook arms 206 engaging the second hook engaging protrusions 206d.
While the fifth embodiment of the drug delivery device employs the cantilever C-arms 208 to effect an elastic occlusion of the full depot channel 203d, it is considered within the scope of the present disclosure to alter a shape of the cantilever C-arms so as extend from single bases, and hence not have a C-shape. It is further considered within the scope of the present disclosure to employ other elastic devices besides cantilever arms to effect an elastic occlusion of the full depot, channel 203d, as related above with respect to the prior embodiments. Additionally, the fifth embodiment may also be modified to have a pellet channel which has a depth less than a diameter of the drug pellets 140 provided that a complimentary channel is formed in the third cartridge plate 200d, or the third cartridge plate 200d is spaced from the fourth cartridge plate 202d to accommodate the drug pellets 140.
Turning next to
Indicia Features
Each of the third and fourth embodiments of the present disclosure comprises ring members which may be used for identification purposes. The first and second ring members, e 210 and 210c, are optionally color coded and/or provided with indicia, 250 and 252, indicating, for example and without limitation, drug type, drug name, dosage, lot no., or expiration date. The provision of the indicia is shown in
Modifications of Embodiments of the Drug Delivery Device
A. Incorporation of Snap Latch in First and Second Embodiment
The funnel body 102 of the first and second embodiment of the drug delivery device does not requite use of a ring member and press fits into the housing body 104 or 104a. While the funnel body 102 is shown in a press fit configuration, it will be understood by those skilled in that art that the funnel body 102 is also modifiable to incorporate the cantilever catch arms, 220 or 220c, and the catch hook protrusions 221 of the third or fourth funnel bodies, 102b or 102c, while modifying the first or second housing body, 104 or 104a, to include the stanchions 240 or the stanchion ring 240c and the included snap engagement apertures, 242 or 242c.
B. Incorporation of Ring Member in First and Second Embodiment
The present disclosure further includes embodiments wherein the ring members, 210 or 210c, are incorporated into either the first or second embodiments described above. Incorporation involves reducing an outer diameter of at least a portion of the funnel body 102 to accept the ring member, 210 or 210, in accordance with the corresponding configurations of the third or fourth funnel bodies, 102b or 102c. Alternatively, or in addition to the adjustment of the funnel body 102, a similar adjustment of the housing body 104 may also be made to accommodate either of the ring members 210 or 210c.
C. Incorporation of Press Fit in Third or Fourth Embodiment
The present disclosure further includes embodiments of the drug delivery device wherein the third or fourth embodiments of the drug delivery device are modified to utilize a press fit of the funnel body into the housing body. The third and fourth embodiments detailed above utilize snap catches to engage the funnel bodies, 102b and 102c, with the housing bodies, 104b and 104c. In order to utilize a press fit engagement as used in the first and second embodiments, the cantilever catch arms, 220 or 220c, and the catch hook protrusions 221 of the second or third funnel bodies, 102b or 102c, may be replaced with a prong to engage in a press fit manner a groove or aperture in modified stanchions of the third or fourth housing bodies, 104 or 104a.
D. Incorporation of First and Second Drug Cartridges into the Third or Fourth Embodiments
The present disclosure further includes embodiments of the drug delivery device wherein the third or fourth embodiments of, the drug delivery device, having ring members and the partially integral drug cartridge, are modified to accept either of the first or second drug cartridge, 130 or 180, in place of the partially integral drug cartridge. The corresponding housing body, 104b or 104c, is modified to include engaging portions of the first or second housing body, namely to incorporate either the receiving channel 162 for the first drug cartridge 102 or the receiving channel 162a for the second drug cartridge 180. Similarly, the corresponding funnel body, 102b or 102c, is modified to eliminate the integral drug cartridge plate 202 and to extend the tubular configuration 151 of the funnel bore 150 to or proximate to the corresponding proximate end of the first or second drug cartridge 130 or 180.
E. Integral Incorporation of Drug Cartridges into the Housing
The drug delivery device of the present disclosure further includes embodiments of the first through fourth above described embodiments wherein the drug cartridge of the respective embodiments is made integral with the housing body. Hence, unless expressly stated otherwise in the appended claims, integration of drug cartridge structure into a housing body is considered to be within the scope of the claims. Thus, claiming a housing body and a drug cartridge does not exclude the drug cartridge being integral with the housing body or parts thereof absent claim language to the contrary.
In the first embodiment the housing body 104 may be formed in first and second housing body halves which respectively incorporate first and second half depot channels which replace depot channel defined by the cartridge tube 132. Cavities are defined by each of the first and second housing body halves which are configure to accept the proximal, and distal O-rings 136 and 134.
In the second, embodiment the housing body 1044 may be formed in first and second housing body halves which respectively incorporate first and second half depot channels which replace a depot channel defined by the half channels of the first and second plates, 182 and 184. The first and second cantilever arms, 194 and 196, are optionally molded into the first and second housing body halves or attached by means known to those skilled in the art. Alternatively, the first and second cantilever arms, 194 and 196, are optionally replaced with deformable devices at positions corresponding to the first and second ramped protrusions. 195 and 197, and which are accepted in cavities defined by one or both of the first and second housing body halves.
In the third and fourth embodiments the housing body, 104b or 104c, may be formed in first and second housing body halves which respectively incorporate first and second half depot channels which replace a depot channel defined by the half channels of the first and second cartridge plates. 200 and 202. The third and fourth cantilever arms, 204 and 208, are optionally molded into the first and second housing body halves or attached by means known to those skilled in the art. Alternatively, the third and fourth cantilever arms, 204 and 208, are optionally replaced with deformable devices at positions corresponding to the romped protrusions. 205 and 207, and which are accepted in cavities defined by one or both of the first and second housing body halves.
E. Adaptation for a Single Occluding Device
The drug delivery device of the present disclosure further includes embodiments of the first through fourth above described embodiments wherein one of the occluding devices is absent. In the absence of the occluding device at the proximate end of the respective drug cartridge, a closing device may be applied to the funnel bore to prevent the drug depot from falling out. In the absence of the occluding device at the distal end of the respective drug cartridge, a closing device may be applied to the nipple channel to prevent the drug depot from falling out.
F. Modification of Cantilever Arms
The second, third and fourth embodiments of the present disclosure include the cantilever arms 194, 195, 204, and 208, respectively having ramped protrusions. 195, 197, 205, and 207. As shown in the figures, the protrusions, 195, 197, 205, and 207, are configured as bumps on the cantilever arms 194, 195, 204, and 208. It is considered to be within the scope and spirit of the present disclosure that in place of the ramped protrusions, 195, 197, 205, and 207, being distinct portions of the cantilever arms 194, 195, 204, and 208, the cantilever arms 194, 195, 204, and 208 may extend in a continuous manner angling into the depot channel so as to protrude sufficiently into the depot channel to prevent passage of a drug depot. As such, both the ramped protrusions, 195, 197.205, and 207, and portions of the cantilever arms 194, 195, 204, and 208, modified to extend into the depot channel are considered to be “protruding portion(s)” of the cantilever arms 194, 195, 204, and 208.
Cannula
The cannula or needle of the drug delivery device is designed to cause minimal physical and psychological trauma to the patient. Cannulas or needles include tubes that may be made from materials, such as for example, polyurethane, polyurea, polyether(amide), PEBA, thermoplastic elastomeric olefin, copolyester, and styrenic thermoplastic elastomer, steel, aluminum, stainless steel, titanium, nitinol, metal alloys with high non-ferrous metal content and a low relative proportion of iron, carbon fiber, glass fiber, plastics, ceramics or combinations thereof. The cannula or needle may optionally include one or more tapered regions. In various embodiments, the cannula or needle may be beveled. The cannula or needle may also have a tip style for accurate treatment of the patient depending on the site for implantation. Examples of tip styles include, for example, Trephine, Cournand, Veress, Huber, Seldinger, Chiba, Francine, Bias, Crawford, deflected tips, Hustead, Lancer, or Tuohey. In various embodiments, the cannula or needle may also be non-coring and have a sheath covering it to Avoid unwanted needle sticks.
The cannula or needle of the drug delivery device has an internal diameter that is larger than the diameter of at least part of the push rod 124 (e.g., tip, middle, etc.) of the plunger 120 to allow at least part of the plunger to be slidably received within the cannula or needle. In various embodiments, the diameter of the cannula or needle is substantially the same throughout. In other embodiments, the diameter of the needle or cannula becomes smaller approaching the distal end for drug delivery.
The dimensions of the hollow cannula or needle, among other things, will depend on the site for implantation. For example, the width of the epidural space is only about 3.5 mm for the thoracic region and about 5-7 mm for the lumbar region. Thus, the needle or cannula, in various embodiments, can be designed for these specific areas. Some examples of lengths of the cannula or needle may include, but are not limited to from about 50 to 150 mm in length, for example, about 65 mm for epidural pediatric use, about 85 mm for a standard adult and about 150 mm for an obese adult patient. The thickness of the cannula or needle will also depend on the site of implantation. In various embodiments the thickness includes, but is not limited to, from about 0.05 to about 1.655. The gauge of the cannula, or needle, may be the widest or smallest diameter or a diameter in between for insertion into a human or animal body. The widest diameter is typically about 14 gauge, while the smallest diameter is about 25 gauge. In various embodiments the gauge of the needle or cannula is about 17 to about 25 gauge.
In various embodiments and those described above, the plunger 120, cannula 110 or drug depot 140 include markings that indicate location at or near the site beneath the skin. Radiographic markers can be included on the drug depot to permit the user to accurately position the depot into the site of the patient. These radiographic markers will also permit the user to track movement and degradation of the depot at the site over time. In this embodiment, the user may accurately position the depot in the site using any of the numerous diagnostic-imaging procedures. Such diagnostic imaging procedures include, for example, X-ray imaging or fluoroscopy. Examples of such radiographic markers include, but are not limited to, barium, calcium phosphate, and/or metal beads.
In various embodiments, the needle or cannula 110 may include a transparent or translucent portion that can be visualizable by ultrasound, fluoroscopy, x-ray, or other imaging techniques. In such embodiments, the transparent or translucent portion may include a radiopaque material or ultrasound responsive topography that increases the contrast of the needle or cannula relative to the absence of the material or topography.
Cannula Coupling Device
In various embodiments of the present disclosure, including those presented above, surrounding the opening of the proximal end of the cannula or needle is a generally cylindrical hub having an engagement means for engaging the housing body. In the above embodiments the housing bodies are shown having internal threading as part of a coupling device. This depiction of a portion of a coupling device is for exemplary purposes only and is not limiting. The present disclosure optionally includes alternative coupling devices which include, but are not limited to, threading, tracks, clips, ribs, projections, and the like that allow a secure connection between the housing and the proximal end of the cannula. For example, in various embodiments the coupling device may be a luer lock connection, where the cannula has mating threads that mate with the threads disposed-on or in the housing.
Housing and Drug Cartridge Material
In various embodiments of the present disclosure, including those presented above, the housing is optionally formed of any of various shapes including, but not limited to, cylindrical or round such that the housing allows for the affixation to the cannula as well as acceptance of the drug cartridge and the plunger. In the embodiments presented above, the housings of the first through fourth embodiments include at least one side configured to prevent rolling of the housing. As illustrated, the housings optionally have a truncated circular cross section presenting opposing substantially flat sides which is an exemplary and non-limiting embodiment.
The housing is optionally provided with contours to allow easy grasping of the device during use for insertion of the drug depot. Furthermore, the housing is optionally angled for right and left hand users or can be generic for both hands.
The housing and drug cartridge is optionally comprised of any of a variety of materials, such as, for example, polyurethane, polyurea, polyether(amide), PEBA, thermoplastic elastomeric olefin, copolyester, and styrenic thermoplastic elastomer, steel, aluminum, stainless steel, titanium, nitinol, metal alloys with high non-ferrous metal content and a low relative proportion of iron, carbon fiber, glass fiber, plastics, ceramics or combinations thereof.
Informative Indicia
In various embodiments of the drug delivery device of the present disclosure, including those presented above, the housing is optionally provided with indicia such dose indicator markings (e.g., numbers, lines, letters, radiographic markers, etc.) to indicate a number and type of drug depots contained in the device and/or delivered into a patient. Additionally, expiration date, lot number, trademarks, application information, and classification of drug are optionally provided on the housing. The indicia is also optionally provided in the form of color coding of at least portions of the housing. Indicia in the third and fourth embodiments is optionally provided on the ring members thereof, but are also optionally provided elsewhere on, the housing bodies. For exemplary purposes and without limitation, the ring members are color coded. In various embodiments, the plunger includes markings that indicate location at or near the site beneath the skin.
Plunger
In each of the aforesaid embodiments of the present disclosure the plunger knob 122 optionally has alignment ridges 125 which are configured to align the plunger knob 122 with any of the funnel bodies, 102, 102a-102c, by virtue of engagement with the funnel bore 150 when the plunger 120 is fully inserted into the drug delivery device. Additionally, the alignment ridges 125 provide structural support for the push rod 125.
Although the first end of the plunger is shown as a knob, it will be understood that the knob can be a top, dial, cap, handle or any member that allows the user to utilize the plunger. The plunger has a second end that includes a tip, which is capable of moving the drug depot within the cannula. In other embodiments, the tip of the plunger is sufficiently pointed so that it is capable of insertion to the site beneath the skin of the patient and the cannula or needle is blunted and used to guide the drug depot to the site.
The plunger has a diameter less than the cannula or needle so that it can be slidably received therein. The plunger may be longer, the same size, or smaller in, length than the cannula or needle. In embodiments where the plunger extends from the distal end of the cannula or needle, the plunger is usually longer than the cannula or needle. In some embodiments, the tip of the plunger can be sharp or blunt.
The plunger may be made from materials, such as for example, polyurethane, polyurea, polyether(amide), PEBA, thermoplastic elastomeric olefin, copolyester, and styrenic thermoplastic elastomer, steel, aluminum, stainless steel, titanium, nitinol, metal alloys with high nonferrous metal content and a low relative proportion of iron, carbon fiber, glass fiber, plastics, ceramics or combinations thereof. The plunger may optionally include one or more, tapered regions.
Like the cannula or needle, in various embodiments, the plunger may have dose indicator markings (e.g., numbers, lines, letters, radiographic markers, etc.) to indicate the number of drug depots delivered. In various embodiments, the plunger includes markings that indicate location at or near the site beneath the skin.
The plunger tip, which may be a complementary shape to the drug pellet, allows the plunger tip to snuggly fit within the end of the drug pellet for easier drug delivery. The drug pellet may have a rounded end for easier insertion at the desired site.
Drug Depot Composition and Manufacture
In various embodiments, including those described above, the dug delivery device optionally comprises at least one drug depot disposed therein during assembly. Alternatively, the drug delivery device is provided assembled without a drug therein and at least one drug depot is breach loaded in to the drug delivery device at a time of use. A further alternative is to provide the various components of the drug delivery device in a kit which allows loading of a drug depot into the drug cartridge of the respective device at the time of assembly.
A drug depot comprises a physical structure to facilitate implantation and retention in a desired site (e.g., a synovial joint, a disc space, a spinal canal, a tissue of the patient, etc.). The drug depot also comprises the drug. The term “drug” as used herein is generally meant to refer to any substance that alters the physiology of the patient. The term “drug” may be used interchangeably herein with the term “therapeutic agent”, “therapeutically effective amount”, and “active pharmaceutical ingredient”. It will be understood that a “drug” formulation may include more than one therapeutic agent, wherein exemplary combinations of therapeutic agents include a combination of two or more drugs. The drug provides a concentration gradient of the therapeutic agent for delivery to the site. In various embodiments, the drug depot provides an optimal drug concentration gradient of the therapeutic agent at a distance of up to about 1 mm to about 5 cm from the implant site.
Examples of drugs suitable for use in the drug depot, include, but are not limited to: an anti-inflammatory agent, analgesic agent, or osteoinductive growth factor or a combination thereof. Anti-inflammatory agents include, but are not limited to, salicylates, diflunisal, indomethacin, ibuprofen, naproxen, tolmetin, ketorolac, diclofenac, ketoprofen, fenamates (mefenamic acid, meclofenamic acid), enolic acids (piroxicam, meloxicam), nabumetone, celecoxib, etodolac, nimesulide, apazone, gold, sulindac or tepoxalin; antioxidants, such as, dithiocarbamate; and other compounds such as sulfasalazine [2-hydroxy-5-[-4-[C2-pyridinylamino)sulfonyl]azo]benzoic acid], steroids, such as fluocinolone, cortisol, cortisone, hydrocortisone, fludrocortisone, prednisone prednisolone, methylprednisolone, triamcinolone, betamethasone, dexamethasone, beclomethasone, fluticasone or protein inhibitors of TNF, such as etanercept, Remicade, IL-1, such as Kineret®, p38, RANK, RANKL, or a combination thereof.
Suitable osteoinductive factors include, but are not limited to, a bone morphogenetic protein, a growth differentiation factor, a LIM mineralization protein or a combination thereof.
Suitable analgesic agents include, but are not limited to, acetaminophen, lidocaine, bupivicaine, opioid analgesics such as buprenorphine, butorphanol, dextromoramide, dezocine, dextropropoxyphene, diamorphine, fentanyl, alfentanil, sufentanil hydrocodone, hydromorphone, ketobemidone, levomethadyl, meperidine, methadone, morphine, nalbuphine, opium, oxycodone, papaveretum, pentazocine, pethidine, phenoperidine, piritramide, dextropropoxyphene, remifentanil, tilidine, tramadol, codeine, dihydrocodeine, meptazinol, dezocine, eptazocine, flupirtine or a combination thereof. Analgesics also include agents with analgesic properties, such as for example, amitriptyline, carbamazepine, gabapentin, pregabalin, clonidine, or a combination thereof.
A “depot” includes but is pot limited to capsules, microspheres, particles, coating, matrices, wafers, pills, pellets or other pharmaceutical delivery compositions. In various embodiments, the depot may comprise a bioerodible, a bioabsorbable, and/or a biodegradable biopolymer that may provide immediate release, or sustained release of the drug. Examples of suitable sustained release biopolymers include but are not limited to poly (alpha-hydroxy acids), poly (lactide-co-glycolide) (PLGA), polylactide (PLA), polyglycolide (PG), polyethylene glycol. (PEG) conjugates of poly (alpha-hydroxy acids), poly(orthoester)s (POE), polyaspirins, polyphosphagenes, collagen, starch, pre-gelatinized starch, hyaluronic acid, chitosans, gelatin, alginates, albumin, fibrin, vitamin E analogs, such as alpha tocopheryl acetate, d-alpha tocopheryl succinate, D,L-lactide, or L-lactide, -caprolactone, dextrans, vinylpyrrolidone, polyvinyl alcohol (PVA), PVA-g-PLGA, PEGT-PBT copolymer (polyactive), methacrylates, poly (N-isopropylacrylamide). PEO-PPO-PEO (pluronics), PEO-PPO-PAA copolymers, PLGA-PEO-PLGA, PEG-PLG, PLA-PLGA, poloxamer 407, PEO-PLGA-PEG triblock copolymers, SAIB (sucrose acetate isobutyrate) or combinations thereof. As persons of ordinary skill are aware, mPEG may be used as a plasticizer for PLGA, but other polymers/excipients may be used to achieve the same effect. mPEG imparts malleability to the resulting formulations. In various embodiments, the drug depot comprises poly(lactide-co-glycolide) (PLGA), polylactide (PLA), polyglycolide (PGA), D-lactide, D,L-lactide, L-lactide, D,L-lactide-ε-caprolactone, D,L-lactide-glycolide-ε-caprolactone or a combination thereof.
In various embodiments, the drug depot comprises drug pellets, as illustrated in the figures of the above described embodiments, loaded with a therapeutically effective amount of the therapeutic agent, wherein the pellets are injected into a synovial joint, a disc space, a spinal canal, or a soft tissue surrounding the spinal canal. In various embodiments, the drug pellets comprise a gel in viscous form and microspheres loaded with a therapeutic agent wherein the combination of gel and microspheres are positioned into a synovial joint, disc space, a spinal canal, or a soft tissue surrounding the spinal canal of a subject.
A “therapeutically effective amount” is-such that when administered, the drug results in alteration of the biological activity, such as, for example, inhibition of inflammation, reduction or alleviation of pain, improvement in the condition, etc. The dosage administered to a patient can be as single or multiple doses depending upon a variety of factors, including the drug's pharmacokinetic properties, the route of administration, patient conditions and characteristics (sex, age, body weight, health, size, etc.), extent of symptoms, concurrent treatments, frequency of treatment and the effect desired.
In the above described exemplary embodiments, the drug depot is in the form of a pellet. The pellet can be any shape, such as for example, bullet shaped, spherical, substantially spherical, flaked, rod shaped (as presented in the figures), square, oval, etc. In various embodiments, the drug pellet has an aspect ratio (a ratio of the length of the pellet divided by the width found at an angle of 90° in respect to the length) which is less than about 1.4 to about 1.05.
The proximal end of the drug pellet may allow the plunger tip to snuggly fit within the proximal end of the drug pellet for easier drug delivery. The distal end of the drug pellet may be rounded for easier insertion at the sites.
In various embodiments, the drug pellet-comprises a bullet-shaped body that is made from a biodegradable material. In alternative embodiments the body of the pellet may be made from a non-biodegradable material. A non-biodegradable body could be a porous hollow chamber filled with the therapeutic agent alone or incorporated into a degradable polymer. It may be desirable to make the body non-degradable to be able to retrieve it after it has released its contents. Non-limiting examples of suitable biodegradable materials for the pellet body include polyorthoesters. (POE), polylacticglycolic acid (PLGA) polysaccarides (Saber technology), polycaprolactone, polyfumarate, tyrosine polycarbonate, etc. The body may be solid, and the therapeutic agent may be dispersed throughout the material that forms the body. The dispersal of the therapeutic agent may be even throughout the body. Alternatively, the concentration of the therapeutic agent may vary throughout the body. As the biodegradable material of the body degrades at the site, the therapeutic agent is released.
Procedures for making pellets include, but are not limited to, extrusion-spheroidization, for spherical pellets where the active pharmaceutical ingredient (API) and any inactive ingredients (excipients, binders etc.) are pre-mixed, then wetted with water, in a high shear mixer to form a damp mass. The damp mass is then transferred into an extruder where it is forced through a screen or die plate, where it forms an essentially, solid, cylindrical extrudate of uniform shape and size. The size of the opening in the screen or die dictate resultant pellet size. The extrudate is fed onto a rotating disk, which may be smooth or may contain a grid (waffled, grooved, etc.) and the extrudate breaks into small cylinders, which in time are rounded into spherically shaped solids. Subsequently, the pellets are dried to the desired residual moisture content, typically in a fluid bed dryer. Any oversized or undersized product is removed by sieving, and the resulting pellets have a narrow size distribution.
In various embodiments, the API is layered on the solid core of the pellet by solution or suspension layering or powder layering techniques. In solution or suspension layering, an API and any inactive ingredients (excipients, binders, etc.) are suspended or dissolved in water or an organic solvent. The resulting liquid is sprayed onto the outside of a core particle, which may include, for example, non-pareil sugar seed (sugar sphere), microcrystalline cellulose pellets and the like, to make the pellet having the desired potency. Solution or suspension layering may be conducted using a wide variety of process techniques, for example, by fluidized bed, Wurster bottom spray techniques, or the like. When the desired potency has been achieved, pellets are dried to the desired residual moisture content. Any oversized or undersized product may be removed by sieving, and the resulting pellets are narrow in size distribution.
Powder layering may also be used to make the drug pellets. Powdered layering involves the application of a dry powder to the pellet core material. The powder may contain the drug, or may include excipients such as a binder, flow aid, inert filler, and the like. In the powder layering technique a pharmaceutically acceptable liquid, which may be water, organic solvent, with or without a binder and/or excipients, is applied to the cote material while applying the dry powder until the desired potency is achieved. When the desired potency has been achieved, the pellets may be seal coated to improve their strength, and are then dried to the desired moisture content. Any oversized or undersized product is removed by sieving, and the resulting pellets are narrow in size distribution.
In one embodiment, the pellet is made using a core of biodegradable material, such as, for example, polyglactin, polylactone, polylactide, etc. The core is then coated with a thin layer of the API, such as an anti-inflamatory agent, analgesic agent, etc. by solution, suspension, or powdered layering until the desired potency is achieved.
In various embodiments, the drug pellets can be different sizes, for example, from about 1 mm to 5 mm in length and have a diameter of from about 0.01 to about 2 mm. The layer or layers will each have a layer thickness of from about 0.005 to 1.0 mm, such as, for example, from 0.05 to 0.75 mm.
Like the cannula, needle, or plunger, in various embodiments, the drug depot (e.g., pellet, cartridge, etc.) may have dose indicator markings (e.g., numbers, lines, letters, radiographic markers, etc.) to indicate the number of drug depots delivered. In various embodiments, radiopaque marks are positioned on the depot at opposite ends of the depot to assist in determining the position of the depot relative to the treatment site. For example, the radiopaque marker could be a spherical shape or a ring around the depot.
Drug Cartridge Material, Loading and Sterilization
In various embodiments, including those presented above, the drug cartridge may be made from materials, such as for example, polyurethane, polyurea, polyether(amide). PEBA, thermoplastic elastomeric olefin, copolyester, and styrenic thermoplastic elastomer, steel, aluminum, stainless steel, titanium, nitinol, metal alloys with high non-ferrous metal content and a low relative proportion of iron, carbon fiber, glass fiber, plastics, ceramics or a combination thereof. In various embodiments, the drug cartridge is not biodegradable.
The drug device components (e.g., cannula or needle, plunger, housing, funnel body, etc.) are optionally lightweight, disposable and sterilizable such that when the device is assembled (e.g., the drug cartridge is loaded the housing), the weight of the device does not substantially increase. In various embodiments, one or mom components of the device an sterilized by radiation in a terminal sterilization step in the final packaging. Terminal sterilization of a product provides greater assurance of sterility than from processes such as an aseptic process, which require individual product components to be sterilized separately and the final package assembled in a sterile environment.
Typically, in various embodiments, gamma radiation is used in the terminal sterilization step, which involves utilizing ionizing energy from gamma rays that penetrates deeply in the device. Gamma rays are highly effective in killing microorganisms, they leave no residues nor have sufficient energy to impart radioactivity to the device. Gamma rays can be employed when the device is in the package and gamma sterilization does not require high pressures or vacuum conditions, thus, package seals and other components are not stressed. In addition, gamma radiation eliminates the need for permeable packaging materials.
In various embodiments, the drug cartridge provides the advantages of ease of manufacturing in the terminal sterilization process. If the drug pellets are preloaded in the manufacturing process, gamma radiation may be required at higher doses to sterilize the drug depot loaded in the cannula or needle. This is particularly so when the cannula or needle is made from steel or metal. Thus, to sterilize the loaded depot, the dose of gamma rays must be high enough to penetrate the metal, which may destroy the API in the drug depot. By providing a drug cartridge, for example, made of plastic, the drug cartridge and drug pellets in the cartridge can be sterilized, without destroying the API and then subsequently loaded by the manufacturer or the user (e.g., surgeon, physician, nurse, etc.). Further, loading the drug depot into the drug chamber or cannula is easier. This is particularly so when dealing with multi-dose drug pellets that are relatively small (e.g., 1 mm to 5 mm), the user typically cannot grasp these small pellets and load them into the device. By providing them in a drug cartridge, the user does not have to substantially manipulate the individual drug pellets, and the risk of contaminating the pellets particularly, with sterilized pellets is reduced.
In various embodiments, electron beam (e-beam) radiation may be used to sterilize one or more components of the device. E-beam radiation comprises a form of ionizing energy, which is generally characterized by low penetration and high-dose rates. E-beam irradiation is similar to gamma processing in that it alters various chemical and molecular bonds on contact, including the reproductive cells of microorganisms. Beams produced for e, beam sterilization Are concentrated, highly-charged streams of electrons generated by the acceleration and conversion of electricity. E-beam sterilization may be used, for example, when the drug depot includes a gelatin capsule.
Other methods may also be used to sterilize one or more components of the device, including, but not limited to, gas sterilization, such as, for example, with ethylene oxide or steam sterilization.
In some embodiments, the housing, drug cartridge, and/or cannula are transparent so, the user can see the position of the plunger and/or the drug depot in the chamber of the drug cartridge. Thus, indicator markings, in this embodiment, are not needed.
Drug Delivery Device Kit
In various embodiments, a kit is provided which may include additional parts along with the drug delivery device combined together to be used to implant the drug depot. The kit may include the drug delivery device in a first compartment. The second compartment may include the drug cartridge, and any other instruments needed for the implant. A third compartment may include gloves, drapes, wound dressings and other procedural supplies for maintaining sterility of the implanting process, as well as an instruction booklet. A fourth compartment may include additional cannulas and/or needles. Each tool may be separately packaged in a plastic pouch that is radiation sterilized. A cover of the kit may include illustrations of the implanting procedure and a clear plastic cover may be placed over the compartments to maintain sterility.
Method of Using the Drug Delivery Device.
In various embodiments of the present disclosure, a method is provided for delivering a drug depot to a site beneath the skin of a patient, the method comprising: assembling a drug delivery device wherein the drug delivery device comprises a cannula having a proximal end and a distal end, the proximal end of the cannula having an opening to receive the drug depot, the distal end of the cannula capable of insertion to the site beneath the skin of the patient and having an opening for passage of the drug depot; a cartridge comprising components to form a secure chamber wherein the secure chamber is capable of storing one or more drug depots in the form of drug pellets, a housing having a top end, a bottom end, and an interior cavity wherein the bottom end of the housing has a coupling means for coupling to the proximal end of the cannula and wherein the interior cavity is configured to receive the cartridge; a plunger having a knob end and a tip end for expelling a drug pellet from the secure chamber, wherein the tip end is slidably receivable within each of the housing, the cartridge, and the cannula to deliver the drug pellet to the site beneath the skin of the patient selecting a drug delivery site beneath the skin of the patient; and dispensing the drug pellet from the drug delivery device to a site beneath the skin of the patient.
In various embodiments, the seal between the plunger tip and the cannula or needle can be air tight so that when the cannula or plunger penetrates the skin at times, fluid (e.g., blood, spinal fluid, synovial fluid, etc.) may be drawn up into the cannula or needle. This fluid will be expelled when the plunger is re-inserted into the cannula or needle and the drug depot is released.
The device may be used for localized and/or targeted delivery of the drug to a patient to treat a disease or condition such as for example, rheumatoid arthritis, osteoarthritis, sciatica, carpal tunnel syndrome, lower back pain, lower extremity pain, upper extremity pain, cancer, post-operative pain, tissue pain and pain associated with injury or repair of cervical, thoracic, and/or lumbar vertebrae or intervertebral discs, rotator cuff, articular joint, TMJ, tendons, ligaments, bone, muscles, and the like.
In various embodiments, the drug delivery device is used to treat pain, or other diseases or conditions of the patient. Pain includes acute pain and neuropathic pain. Acute pain refers to pain experienced when tissue is being damaged or is damaged (e.g., injury, infection, etc.). As contrasted to acute pain, neuropathic pain serves no beneficial purpose. Neuropathic pain results when pain associated with an injury or infection continues in an area once the injury or infection has resolved. Sciatica provides an example of pain that can transition from acute to neuropathic pain. Sciatica refers to pain associated with the sciatic nerve which runs from the lower part of the spinal cord (the lumbar region), down the back of the leg and to the foot. Sciatica generally begins with a herniated disc. The herniated disc itself leads to local immune system activation. The herniated disc also may damage the nerve root by pinching or compressing it, leading to additional immune system activation in the area.
Patients include a biological system to which a treatment can be administered. A biological system can include, for example, an individual cell, a set of cells (e.g., a cell culture), an organ, or a tissue. Additionally, the term “patient” can refer to animals, including, without limitation, humans.
Treating or treatment of a disease refers to executing a protocol, which may include administering one or more drugs to a patient (human Or otherwise), in an effort to alleviate signs or symptoms of the disease. Alleviation can occur prior to signs or symptoms of the disease appearing, as well as after their appearance. Thus, “treating” or “treatment” includes “preventing” or “prevention” of disease. In addition, “treating” or “treatment” does not require complete alleviation of signs or symptoms, does not require a cure, and specifically includes protocols that have only a marginal effect on the patient.
“Localized” delivery includes, delivery where one or more drugs are deposited within a tissue, for example, a nerve root of the nervous system or a region of the brain, or in close proximity (within about 10 cm, or preferably within about 5 cm, for example) thereto. “Targeted delivery system” provides delivery of one or more drugs depots in a quantity of pharmaceutical composition that can be deposited at the target site as needed for treatment of pain, inflammation or other disease or condition.
It will be apparent to those skilled in the art that various modifications and variations can be made to various embodiments described herein-without departing from the spirit or scope of the teachings herein. Thus, it is intended that various embodiments cover other modifications and variations of various embodiments within the scope of the present teachings.
| Number | Name | Date | Kind |
|---|---|---|---|
| 797183 | Davis | Oct 1904 | A |
| 1881854 | Muir | Oct 1932 | A |
| 2502909 | Wick et al. | Apr 1950 | A |
| 2513014 | Fields | Jun 1950 | A |
| 2883984 | Candido, Jr. et al. | Apr 1959 | A |
| 3016895 | Sein | Jan 1962 | A |
| 3520299 | Tapper et al. | Jul 1970 | A |
| 3620216 | Szymanski | Nov 1971 | A |
| 4044989 | Basel et al. | Aug 1977 | A |
| 4069825 | Akiyama | Jan 1978 | A |
| 4105030 | Kercso | Aug 1978 | A |
| 4164560 | Folkman et al. | Aug 1979 | A |
| D262156 | Grubelnig | Dec 1981 | S |
| 4344431 | Yolles | Aug 1982 | A |
| 4346709 | Schmitt | Aug 1982 | A |
| 4402308 | Scott | Sep 1983 | A |
| 4427015 | Redeaux | Jan 1984 | A |
| 4451253 | Harman | May 1984 | A |
| 4516593 | Muto | May 1985 | A |
| 4525156 | Benusa et al. | Jun 1985 | A |
| 4531938 | Kaye et al. | Jul 1985 | A |
| 4559054 | Bruck | Dec 1985 | A |
| 4576591 | Kaye et al. | Mar 1986 | A |
| 4624255 | Schenck et al. | Nov 1986 | A |
| 4624848 | Lee | Nov 1986 | A |
| 4700692 | Baumgartner | Oct 1987 | A |
| 4742054 | Naftchi | May 1988 | A |
| 4762515 | Grimm | Aug 1988 | A |
| 4774091 | Yamahira et al. | Sep 1988 | A |
| 4781695 | Dalton | Nov 1988 | A |
| 4791939 | Maillard | Dec 1988 | A |
| 4819684 | Zaugg et al. | Apr 1989 | A |
| 4820267 | Harman | Apr 1989 | A |
| 4820284 | Hauri | Apr 1989 | A |
| 4855335 | Neperud | Aug 1989 | A |
| 4863457 | Lee | Sep 1989 | A |
| 4871094 | Gall et al. | Oct 1989 | A |
| 4892538 | Patrick et al. | Jan 1990 | A |
| 4900304 | Fujioka et al. | Feb 1990 | A |
| 4909250 | Smith | Mar 1990 | A |
| 4936827 | Grimm et al. | Jun 1990 | A |
| 4941874 | Sandow et al. | Jul 1990 | A |
| 5024655 | Freeman et al. | Jun 1991 | A |
| 5024841 | Chu et al. | Jun 1991 | A |
| 5131401 | Westenskow et al. | Jul 1992 | A |
| D328644 | Pericic | Aug 1992 | S |
| 5135493 | Peschke | Aug 1992 | A |
| 5163904 | Lampropoulos et al. | Nov 1992 | A |
| 5180716 | Yaksh et al. | Jan 1993 | A |
| 5183470 | Wettermann | Feb 1993 | A |
| 5196015 | Neubardt | Mar 1993 | A |
| 5207678 | Harms et al. | May 1993 | A |
| 5212162 | Missel et al. | May 1993 | A |
| 5236426 | Schottes et al. | Aug 1993 | A |
| 5284479 | De Jong | Feb 1994 | A |
| 5312351 | Gerrone | May 1994 | A |
| 5330768 | Park et al. | Jul 1994 | A |
| 5337735 | Salerno | Aug 1994 | A |
| D353668 | Banks | Dec 1994 | S |
| 5391081 | Lampotang et al. | Feb 1995 | A |
| D362064 | Smick | Sep 1995 | S |
| 5449351 | Zohmann | Sep 1995 | A |
| 5466219 | Lynn et al. | Nov 1995 | A |
| 5474558 | Neubardt | Dec 1995 | A |
| 5484403 | Yoakum et al. | Jan 1996 | A |
| 5487739 | Aebischer et al. | Jan 1996 | A |
| 5514101 | Schulz et al. | May 1996 | A |
| 5520660 | Loos et al. | May 1996 | A |
| 5522844 | Johnson | Jun 1996 | A |
| D373823 | Baldwin | Sep 1996 | S |
| 5558637 | Allonen et al. | Sep 1996 | A |
| 5571882 | Velter | Nov 1996 | A |
| 5622940 | Ostroff et al. | Apr 1997 | A |
| 5626838 | Cavanaugh, Jr. | May 1997 | A |
| 5633002 | Stricker et al. | May 1997 | A |
| 5694920 | Abrams et al. | Dec 1997 | A |
| 5695463 | Cherif-Cheikh | Dec 1997 | A |
| 5725508 | Chanoch et al. | Mar 1998 | A |
| 5733572 | Unger et al. | Mar 1998 | A |
| 5752930 | Rise et al. | May 1998 | A |
| 5756127 | Grisoni et al. | May 1998 | A |
| 5759583 | Iwamoto et al. | Jun 1998 | A |
| 5772671 | Harmon | Jun 1998 | A |
| 5827234 | Loos et al. | Oct 1998 | A |
| 5829589 | Nguyen et al. | Nov 1998 | A |
| 5830130 | Janzen et al. | Nov 1998 | A |
| 5834001 | Dionne et al. | Nov 1998 | A |
| 5868789 | Huebner | Feb 1999 | A |
| 5902273 | Yang et al. | May 1999 | A |
| 5928130 | Schmidt | Jul 1999 | A |
| 5928158 | Aristides | Jul 1999 | A |
| 5942241 | Chasin et al. | Aug 1999 | A |
| 5980927 | Nelson et al. | Nov 1999 | A |
| 6001386 | Ashton et al. | Dec 1999 | A |
| 6007843 | Drizen et al. | Dec 1999 | A |
| 6015557 | Tobinick et al. | Jan 2000 | A |
| 6036978 | Gombotz et al. | Mar 2000 | A |
| 6063057 | Choh | May 2000 | A |
| 6069129 | Sandberg et al. | May 2000 | A |
| 6083534 | Wallach et al. | Jul 2000 | A |
| 6086614 | Mumme | Jul 2000 | A |
| 6102844 | Ravins et al. | Aug 2000 | A |
| 6132420 | Dionne et al. | Oct 2000 | A |
| 6179862 | Sawhney | Jan 2001 | B1 |
| 6190350 | Davis et al. | Feb 2001 | B1 |
| 6193692 | Harris et al. | Feb 2001 | B1 |
| 6203813 | Gooberman | Mar 2001 | B1 |
| 6214370 | Nelson et al. | Apr 2001 | B1 |
| 6235289 | Aoki et al. | May 2001 | B1 |
| 6242004 | Rault | Jun 2001 | B1 |
| 6248345 | Goldenheim et al. | Jun 2001 | B1 |
| 6258056 | Turley et al. | Jul 2001 | B1 |
| 6273877 | West et al. | Aug 2001 | B1 |
| 6277969 | Le et al. | Aug 2001 | B1 |
| 6287588 | Shih et al. | Sep 2001 | B1 |
| 6298256 | Meyer | Oct 2001 | B1 |
| 6326020 | Kohane et al. | Dec 2001 | B1 |
| 6331311 | Brodbeck et al. | Dec 2001 | B1 |
| 6350251 | Prosl | Feb 2002 | B1 |
| 6391005 | Lum et al. | May 2002 | B1 |
| 6413245 | Yaacobi et al. | Jul 2002 | B1 |
| 6428804 | Suzuki et al. | Aug 2002 | B1 |
| 6450937 | Mercereau et al. | Sep 2002 | B1 |
| 6461631 | Dunn et al. | Oct 2002 | B1 |
| 6471688 | Harper et al. | Oct 2002 | B1 |
| 6478768 | Kneer | Nov 2002 | B1 |
| 6478776 | Rosenman et al. | Nov 2002 | B1 |
| 6478790 | Bardani | Nov 2002 | B2 |
| 6488649 | Lichten | Dec 2002 | B1 |
| 6497729 | Moussy et al. | Dec 2002 | B1 |
| 6524607 | Goldenheim et al. | Feb 2003 | B1 |
| 6530934 | Jacobsen et al. | Mar 2003 | B1 |
| 6531154 | Mathiowitz et al. | Mar 2003 | B1 |
| 6534081 | Goldenheim et al. | Mar 2003 | B2 |
| 6551290 | Elsberry et al. | Apr 2003 | B1 |
| 6554778 | Fleming | Apr 2003 | B1 |
| 6565541 | Sharp | May 2003 | B2 |
| 6571125 | Thompson | May 2003 | B2 |
| 6582441 | He et al. | Jun 2003 | B1 |
| 6589549 | Shih et al. | Jul 2003 | B2 |
| 6594880 | Elsberry | Jul 2003 | B2 |
| 6616946 | Meier et al. | Sep 2003 | B1 |
| 6630155 | Chandrashekar et al. | Oct 2003 | B1 |
| 6632457 | Sawhney | Oct 2003 | B1 |
| 6648849 | Tenhuisen et al. | Nov 2003 | B2 |
| 6652883 | Goupil et al. | Nov 2003 | B2 |
| 6673333 | Meade et al. | Jan 2004 | B1 |
| 6676971 | Goupil et al. | Jan 2004 | B2 |
| 6710126 | Hirt et al. | Mar 2004 | B1 |
| 6723741 | Jeon et al. | Apr 2004 | B2 |
| 6723814 | Meier et al. | Apr 2004 | B2 |
| 6735475 | Whitehurst et al. | May 2004 | B1 |
| 6756058 | Brubaker et al. | Jul 2004 | B2 |
| 6773714 | Dunn et al. | Aug 2004 | B2 |
| 6837865 | Kneer | Jan 2005 | B2 |
| 6869426 | Ganem | Mar 2005 | B2 |
| 6916308 | Dixon et al. | Jul 2005 | B2 |
| 6921541 | Chasin et al. | Jul 2005 | B2 |
| 6936270 | Watson et al. | Aug 2005 | B2 |
| 6971998 | Rosenman et al. | Dec 2005 | B2 |
| 6974462 | Sater | Dec 2005 | B2 |
| 6982089 | Tobinick | Jan 2006 | B2 |
| 6993375 | Burbank et al. | Jan 2006 | B2 |
| 7001892 | Chmielewski et al. | Feb 2006 | B1 |
| 7012106 | Yuan et al. | Mar 2006 | B2 |
| 7018384 | Skakoon | Mar 2006 | B2 |
| 7070583 | Higuchi et al. | Jul 2006 | B1 |
| 7070809 | Goupil et al. | Jul 2006 | B2 |
| 7081123 | Merboth et al. | Jul 2006 | B2 |
| 7108153 | Wood | Sep 2006 | B2 |
| 7144412 | Wolf et al. | Dec 2006 | B2 |
| 7166570 | Hunter et al. | Jan 2007 | B2 |
| 7204826 | Tremaglio et al. | Apr 2007 | B2 |
| 7212865 | Cory | May 2007 | B2 |
| 7215426 | Tsuyuki et al. | May 2007 | B2 |
| 7220281 | Lambrecht et al. | May 2007 | B2 |
| 7223289 | Trieu et al. | May 2007 | B2 |
| 7229441 | Trieu et al. | Jun 2007 | B2 |
| 7235043 | Gellman et al. | Jun 2007 | B2 |
| 7252651 | Haider et al. | Aug 2007 | B2 |
| 7252685 | Bindseil et al. | Aug 2007 | B2 |
| 7276477 | Osslund et al. | Oct 2007 | B2 |
| 7287983 | Ilan | Oct 2007 | B2 |
| 7302960 | Patzer | Dec 2007 | B2 |
| 7317091 | Lazar et al. | Jan 2008 | B2 |
| 7318840 | McKay | Jan 2008 | B2 |
| D561896 | Jones | Feb 2008 | S |
| 7329259 | Cragg | Feb 2008 | B2 |
| 7344716 | Di Mauro et al. | Mar 2008 | B2 |
| 7355008 | Stavenhagen et al. | Apr 2008 | B2 |
| 7357792 | Newton et al. | Apr 2008 | B2 |
| 7361168 | Makower et al. | Apr 2008 | B2 |
| 7367978 | Drewry et al. | May 2008 | B2 |
| D571463 | Chesnin | Jun 2008 | S |
| 7400930 | Sharkey et al. | Jul 2008 | B2 |
| 7585280 | Wilson et al. | Sep 2009 | B2 |
| 7618370 | Choi et al. | Nov 2009 | B2 |
| D606190 | Pruitt | Dec 2009 | S |
| 7637279 | Amley et al. | Dec 2009 | B2 |
| 7700100 | Johnson et al. | Apr 2010 | B2 |
| D616095 | Kim | May 2010 | S |
| 7727954 | McKay | Jun 2010 | B2 |
| 7741273 | McKay | Jun 2010 | B2 |
| D624653 | Boillat | Sep 2010 | S |
| 7798988 | Aubert et al. | Sep 2010 | B2 |
| D630733 | Ahlgren | Jan 2011 | S |
| 7955301 | McKay | Jun 2011 | B1 |
| 7998108 | Nazzaro et al. | Aug 2011 | B2 |
| 8029458 | Cherif-Cheikh et al. | Oct 2011 | B2 |
| 8029478 | Zanella | Oct 2011 | B2 |
| 8084582 | Dahiyat et al. | Dec 2011 | B2 |
| 8088119 | Saal et al. | Jan 2012 | B2 |
| 8092424 | Mueller et al. | Jan 2012 | B2 |
| 8221358 | McKay | Jul 2012 | B2 |
| 8246571 | Simonton et al. | Aug 2012 | B2 |
| 8267895 | McKay | Sep 2012 | B2 |
| 8337453 | Lind | Dec 2012 | B2 |
| 8357388 | McKay | Jan 2013 | B2 |
| 8481064 | McKay | Jul 2013 | B2 |
| 8485180 | Smutney et al. | Jul 2013 | B2 |
| 8585655 | Bierman | Nov 2013 | B2 |
| 8608705 | Peters et al. | Dec 2013 | B2 |
| 8652092 | Bussmann | Feb 2014 | B2 |
| 8702677 | Simonton et al. | Apr 2014 | B2 |
| 8715223 | McKay | May 2014 | B2 |
| 8790293 | Nazzaro et al. | Jul 2014 | B2 |
| D711542 | Pierson | Aug 2014 | S |
| 8834412 | Painchaud et al. | Sep 2014 | B2 |
| D715929 | Khalaj | Oct 2014 | S |
| 8992458 | Singh et al. | Mar 2015 | B2 |
| 8998854 | McKay | Apr 2015 | B2 |
| 9050415 | Shetty et al. | Jun 2015 | B2 |
| D737435 | Ha et al. | Aug 2015 | S |
| D751702 | Eaton et al. | Mar 2016 | S |
| 9271754 | Ostrovsky et al. | Mar 2016 | B2 |
| 9381111 | Hickingbotham et al. | Jul 2016 | B2 |
| D782037 | Osypka | Mar 2017 | S |
| 9764122 | Clay et al. | Sep 2017 | B2 |
| 9775978 | Clay et al. | Oct 2017 | B2 |
| D802755 | Snyder | Nov 2017 | S |
| D802756 | Snyder | Nov 2017 | S |
| D802757 | Snyder et al. | Nov 2017 | S |
| 9867974 | Beebe et al. | Jan 2018 | B2 |
| D809652 | Snyder et al. | Feb 2018 | S |
| 10076650 | Koch et al. | Sep 2018 | B2 |
| 10080877 | Clay et al. | Sep 2018 | B2 |
| 10272234 | Wetzel et al. | Apr 2019 | B2 |
| 10342966 | Shetty et al. | Jul 2019 | B2 |
| 10384048 | Clay et al. | Aug 2019 | B2 |
| 10391291 | Wallace et al. | Aug 2019 | B2 |
| 10405955 | Eisele et al. | Sep 2019 | B2 |
| 10434261 | Snyder | Oct 2019 | B2 |
| 10478603 | Clay et al. | Nov 2019 | B2 |
| 10549081 | Snyder | Feb 2020 | B2 |
| 20010005785 | Sachse | Jun 2001 | A1 |
| 20010020147 | Staniforth et al. | Sep 2001 | A1 |
| 20010031940 | Loos | Oct 2001 | A1 |
| 20010033867 | Ahern et al. | Oct 2001 | A1 |
| 20010043915 | Frey | Nov 2001 | A1 |
| 20020009454 | Boone et al. | Jan 2002 | A1 |
| 20020022800 | O'Holloran et al. | Feb 2002 | A1 |
| 20020082583 | Lerner | Jun 2002 | A1 |
| 20020090398 | Dunn et al. | Jul 2002 | A1 |
| 20020116022 | Lebouitz et al. | Aug 2002 | A1 |
| 20020198527 | Muckter | Dec 2002 | A1 |
| 20030004491 | Tenhuisen et al. | Jan 2003 | A1 |
| 20030009235 | Manrique et al. | Jan 2003 | A1 |
| 20030023310 | Lubeck et al. | Jan 2003 | A1 |
| 20030036673 | Schmidt | Feb 2003 | A1 |
| 20030039613 | Unger et al. | Feb 2003 | A1 |
| 20030045808 | Kaula et al. | Mar 2003 | A1 |
| 20030144570 | Hunter et al. | Jul 2003 | A1 |
| 20030171637 | Terwilliger et al. | Sep 2003 | A1 |
| 20030171954 | Guerin et al. | Sep 2003 | A1 |
| 20030185873 | Chasin et al. | Oct 2003 | A1 |
| 20030204191 | Sater et al. | Oct 2003 | A1 |
| 20030224033 | Li et al. | Dec 2003 | A1 |
| 20040015133 | Karim | Jan 2004 | A1 |
| 20040015149 | Palasis | Jan 2004 | A1 |
| 20040034357 | Beane et al. | Feb 2004 | A1 |
| 20040054338 | Bybordi et al. | Mar 2004 | A1 |
| 20040064088 | Gorman et al. | Apr 2004 | A1 |
| 20040064193 | Evans et al. | Apr 2004 | A1 |
| 20040065615 | Hooper et al. | Apr 2004 | A1 |
| 20040072799 | Li et al. | Apr 2004 | A1 |
| 20040082540 | Hermida Ochoa | Apr 2004 | A1 |
| 20040082908 | Whitehurst et al. | Apr 2004 | A1 |
| 20040098113 | Forsell et al. | May 2004 | A1 |
| 20040106914 | Coppeta et al. | Jun 2004 | A1 |
| 20040109893 | Chen et al. | Jun 2004 | A1 |
| 20040111118 | Hill et al. | Jun 2004 | A1 |
| 20040162574 | Viola | Aug 2004 | A1 |
| 20040214793 | Hermida Ochoa | Oct 2004 | A1 |
| 20040220545 | Heruth et al. | Nov 2004 | A1 |
| 20040220546 | Heruth et al. | Nov 2004 | A1 |
| 20040220547 | Heruth et al. | Nov 2004 | A1 |
| 20040220548 | Heruth et al. | Nov 2004 | A1 |
| 20040228901 | Trieu et al. | Nov 2004 | A1 |
| 20040229878 | DiMauro et al. | Nov 2004 | A1 |
| 20040249464 | Bindseil et al. | Dec 2004 | A1 |
| 20050025765 | DiMauro et al. | Feb 2005 | A1 |
| 20050043673 | Lieberman | Feb 2005 | A1 |
| 20050070843 | Gonzales | Mar 2005 | A1 |
| 20050074481 | Brekke et al. | Apr 2005 | A1 |
| 20050079202 | Chen et al. | Apr 2005 | A1 |
| 20050107756 | McCraw | May 2005 | A1 |
| 20050137579 | Heruth et al. | Jun 2005 | A1 |
| 20050142163 | Hunter et al. | Jun 2005 | A1 |
| 20050143689 | Ramsey, III | Jun 2005 | A1 |
| 20050152905 | Omoigui | Jul 2005 | A1 |
| 20050152949 | Hotchkiss et al. | Jul 2005 | A1 |
| 20050175709 | Baty, III et al. | Aug 2005 | A1 |
| 20050177118 | Hoganson et al. | Aug 2005 | A1 |
| 20050177135 | Hildebrand et al. | Aug 2005 | A1 |
| 20050178779 | Wood | Aug 2005 | A1 |
| 20050184264 | Tesluk et al. | Aug 2005 | A1 |
| 20050186261 | Avelar et al. | Aug 2005 | A1 |
| 20050197293 | Mellis et al. | Sep 2005 | A1 |
| 20050203542 | Weber et al. | Sep 2005 | A1 |
| 20050245906 | Makower et al. | Nov 2005 | A1 |
| 20050249775 | Falotico et al. | Nov 2005 | A1 |
| 20050228620 | Shippert | Dec 2005 | A1 |
| 20050278023 | Zwirkoski | Dec 2005 | A1 |
| 20050287218 | Chaouk et al. | Dec 2005 | A1 |
| 20050288789 | Chaouk et al. | Dec 2005 | A1 |
| 20060046960 | McKay et al. | Mar 2006 | A1 |
| 20060046961 | McKay et al. | Mar 2006 | A1 |
| 20060074422 | Story et al. | Apr 2006 | A1 |
| 20060084943 | Roseman et al. | Apr 2006 | A1 |
| 20060100622 | Jackson | May 2006 | A1 |
| 20060106361 | Muni et al. | May 2006 | A1 |
| 20060121032 | Dahiyat et al. | Jun 2006 | A1 |
| 20060148903 | Burch et al. | Jul 2006 | A1 |
| 20060153815 | Seyda et al. | Jul 2006 | A1 |
| 20060161114 | Perot et al. | Jul 2006 | A1 |
| 20060183786 | Wang | Aug 2006 | A1 |
| 20060189944 | Campbell et al. | Aug 2006 | A1 |
| 20060228391 | Seyedin et al. | Oct 2006 | A1 |
| 20060253100 | Burright et al. | Nov 2006 | A1 |
| 20060264839 | Veasey et al. | Nov 2006 | A1 |
| 20070005005 | Wang | Jan 2007 | A1 |
| 20070021358 | Edelman et al. | Jan 2007 | A1 |
| 20070043359 | Altarac et al. | Feb 2007 | A1 |
| 20070055378 | Ankney et al. | Mar 2007 | A1 |
| 20070066864 | Forde | Mar 2007 | A1 |
| 20070104769 | Feng et al. | May 2007 | A1 |
| 20070106247 | Burnett et al. | May 2007 | A1 |
| 20070118142 | Krueger et al. | May 2007 | A1 |
| 20070123863 | Winslow et al. | May 2007 | A1 |
| 20070129744 | Teichert et al. | Jun 2007 | A1 |
| 20070149992 | Teng | Jun 2007 | A1 |
| 20070156180 | Jaax et al. | Jul 2007 | A1 |
| 20070179474 | Cahill et al. | Aug 2007 | A1 |
| 20070185497 | Cauthen et al. | Aug 2007 | A1 |
| 20070202074 | Shalaby | Aug 2007 | A1 |
| 20070219564 | Rue et al. | Sep 2007 | A1 |
| 20070233038 | Pruit et al. | Oct 2007 | A1 |
| 20070243225 | McKay | Oct 2007 | A1 |
| 20070243228 | McKay | Oct 2007 | A1 |
| 20070244442 | Chowhan | Oct 2007 | A1 |
| 20070248639 | Demopulos et al. | Oct 2007 | A1 |
| 20070249632 | Zentner | Oct 2007 | A1 |
| 20070253994 | Hildebrand | Nov 2007 | A1 |
| 20070255281 | Simonton et al. | Nov 2007 | A1 |
| 20070255282 | Simonton et al. | Nov 2007 | A1 |
| 20070260184 | Justis et al. | Nov 2007 | A1 |
| 20070260201 | Prausnitz et al. | Nov 2007 | A1 |
| 20070265582 | Kaplan et al. | Nov 2007 | A1 |
| 20080004570 | Simonton et al. | Jan 2008 | A1 |
| 20080004703 | Trieu et al. | Jan 2008 | A1 |
| 20080009830 | Fujimoto et al. | Jan 2008 | A1 |
| 20080021074 | Cartt | Jan 2008 | A1 |
| 20080038351 | Beals et al. | Feb 2008 | A1 |
| 20080065029 | Racz | Mar 2008 | A1 |
| 20080077093 | Gratwohl et al. | Mar 2008 | A1 |
| 20080091207 | Truckai et al. | Apr 2008 | A1 |
| 20080097229 | Roy et al. | Apr 2008 | A1 |
| 20080102097 | Zanella | May 2008 | A1 |
| 20080125637 | Geist et al. | May 2008 | A1 |
| 20080139877 | Chu et al. | Jun 2008 | A1 |
| 20080208138 | Lim et al. | Aug 2008 | A1 |
| 20080215001 | Cowe | Sep 2008 | A1 |
| 20080228193 | Matityahu | Sep 2008 | A1 |
| 20080294039 | Jones et al. | Nov 2008 | A1 |
| 20090053211 | Lazar et al. | Feb 2009 | A9 |
| 20090088809 | Fisher et al. | Apr 2009 | A1 |
| 20090099597 | Isse | Apr 2009 | A1 |
| 20090148500 | Lawter et al. | Jun 2009 | A1 |
| 20090177141 | Kucklick | Jul 2009 | A1 |
| 20090182267 | Painchaud et al. | Jul 2009 | A1 |
| 20090209804 | Seiler et al. | Aug 2009 | A1 |
| 20090246123 | Zanella et al. | Oct 2009 | A1 |
| 20090263319 | Wohabrebbi et al. | Oct 2009 | A1 |
| 20090263321 | McDonald et al. | Oct 2009 | A1 |
| 20090263441 | McKay | Oct 2009 | A1 |
| 20090263459 | King et al. | Oct 2009 | A1 |
| 20090263460 | McDonald | Oct 2009 | A1 |
| 20090264490 | Zanella et al. | Oct 2009 | A1 |
| 20090264491 | McKay et al. | Oct 2009 | A1 |
| 20090270797 | Aubert et al. | Oct 2009 | A1 |
| 20090292246 | Slate | Nov 2009 | A1 |
| 20100015049 | Wohabrebbi | Jan 2010 | A1 |
| 20100106132 | Simonton | Apr 2010 | A1 |
| 20100106136 | Simonton | Apr 2010 | A1 |
| 20100106137 | Simonton et al. | Apr 2010 | A1 |
| 20100160375 | King | Jun 2010 | A1 |
| 20100163059 | Tierney et al. | Jul 2010 | A1 |
| 20100198140 | Lawson | Aug 2010 | A1 |
| 20100249750 | Racz | Sep 2010 | A1 |
| 20100331868 | Bardy | Dec 2010 | A1 |
| 20100331874 | Bardy | Dec 2010 | A1 |
| 20110098675 | Schmalz | Apr 2011 | A1 |
| 20110104233 | Drapeau | May 2011 | A1 |
| 20110106110 | McKay | May 2011 | A1 |
| 20110152755 | Schmalz | Jun 2011 | A1 |
| 20110182849 | Haddock et al. | Jul 2011 | A1 |
| 20110202011 | Wozencrift | Aug 2011 | A1 |
| 20110313393 | Zanella | Dec 2011 | A1 |
| 20120022568 | Koblish et al. | Jan 2012 | A1 |
| 20120142648 | Biggs et al. | Jun 2012 | A1 |
| 20120142747 | Wilsey et al. | Jun 2012 | A1 |
| 20130116556 | Racz | May 2013 | A1 |
| 20130178822 | Hickingbotham et al. | Jul 2013 | A1 |
| 20130211328 | Plumptre et al. | Aug 2013 | A1 |
| 20130261596 | McKay | Oct 2013 | A1 |
| 20140277459 | McCarthy | Sep 2014 | A1 |
| 20160263364 | Eisele et al. | Sep 2016 | A1 |
| 20160296739 | Cleveland | Oct 2016 | A1 |
| 20160354115 | Smith et al. | Dec 2016 | A1 |
| 20170231716 | Ahari et al. | Aug 2017 | A1 |
| 20170354811 | Clay et al. | Dec 2017 | A1 |
| 20180126090 | Snyder | May 2018 | A1 |
| 20190015653 | Koch et al. | Jan 2019 | A1 |
| 20190054253 | Kneer et al. | Feb 2019 | A1 |
| 20190247638 | Murphy | Aug 2019 | A1 |
| 20190255308 | Virden | Aug 2019 | A1 |
| 20190262115 | Eisele et al. | Aug 2019 | A1 |
| 20190374762 | Clay et al. | Dec 2019 | A1 |
| 20200030545 | Snyder | Jan 2020 | A1 |
| 20200171291 | Snyder | Jun 2020 | A1 |
| 20210236787 | Koch et al. | Aug 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 102056564 | May 2011 | CN |
| 205073422 | Mar 2016 | CN |
| 1955059 | Feb 1967 | DE |
| 19640670 | May 1998 | DE |
| 0 548 612 | Jun 1993 | EP |
| 1 216 721 | Jun 2002 | EP |
| 1 323 450 | Sep 2004 | EP |
| 1 518 549 | Feb 2007 | EP |
| 1 625 870 | May 2008 | EP |
| 2 008 596 | Dec 2008 | EP |
| 1 270 590 | Sep 1961 | FR |
| 2 007 684 | Jan 1970 | FR |
| 2 231 355 | Dec 1974 | FR |
| 1379358 | Jan 1975 | GB |
| 2006-509531 | Mar 2006 | JP |
| 2009-160395 | Jul 2009 | JP |
| 10-2006-0120103 | Nov 2006 | KR |
| WO 9320859 | Oct 1993 | WO |
| WO 9401166 | Jan 1994 | WO |
| WO 1999052573 | Oct 1999 | WO |
| WO 2000038574 | Jul 2000 | WO |
| WO 2001062272 | Aug 2001 | WO |
| WO 2002034116 | May 2002 | WO |
| WO 2002085188 | Oct 2002 | WO |
| WO 2003005961 | Jan 2003 | WO |
| WO 2004009776 | Jan 2004 | WO |
| WO 2004050688 | Jun 2004 | WO |
| WO 2004084819 | Oct 2004 | WO |
| WO 2005018468 | Mar 2005 | WO |
| WO 2005034998 | Apr 2005 | WO |
| WO 2007121288 | Oct 2007 | WO |
| WO 2008067362 | Jun 2008 | WO |
| WO 2008091777 | Jul 2008 | WO |
| WO 2009049823 | Apr 2009 | WO |
| WO 2009134314 | Nov 2009 | WO |
| WO 2010011526 | Jan 2010 | WO |
| WO 2016014300 | Jan 2016 | WO |
| WO 2019028138 | Feb 2019 | WO |
| WO 2019125457 | Jun 2019 | WO |
| Entry |
|---|
| U.S. Appl. No. 08/386,853, filed Feb. 10, 1995, Method and Device for Administering Analgesics. |
| U.S. Appl. No. 08/775,528 (U.S. Pat. No. 5,980,927), filed Jan. 2, 1997 (Nov. 9, 1999), Method and Apparatus for Administering Analgesics, and Method for Making Same. |
| U.S. Appl. No. 09/291,571 (U.S. Pat. No. 6,214,370), filed Apr. 9, 1999 (Apr. 10, 2001), Method and Device for Administering Analgesics. |
| U.S. Appl. No. 10/932,878, filed Sep. 2, 2004, Controlled and Directed Local Delivery of Anti-Inflammatory Compositions. |
| U.S. Appl. No. 11/091,348, filed Mar. 28, 2005, Controlled and Directed Local Delivery of Anti-Inflammatory Compositions. |
| U.S. Appl. No. 11/932,442 (U.S. Pat. No. 8,029,478), filed Oct. 31, 2007 (Oct. 4, 2011), Implant Device and Method for Delivering Drug Depots to a Site Beneath the Skin. |
| U.S. Appl. No. 13/220,086, filed Aug. 29, 2011, Implantable Device and Method for Delivering Drug Depots to a Site Beneath the Skin. |
| U.S. Appl. No. 11/942,820 (U.S. Pat. No. 8,221,358), filed Nov. 20, 2007 (Jul. 17, 2012), Devices and Methods for Delivering Drug Depots to a Site Beneath the Skin. |
| U.S. Appl. No. 12/260,673, filed Oct. 29, 2008, Drug Delivery Device With Sliding Cartridge. |
| U.S. Appl. No. 12/260,683, filed Oct. 29, 2008, Drug Delivery System. |
| U.S. Appl. No. 12/260,700, filed Oct. 29, 2008, Drug Cartridge for Delivering a Drug Depot Comprising Superior and Inferior Covers. |
| U.S. Appl. No. 12/262,823 (U.S. Pat. No. 8,702,677), filed Oct. 31, 2008 (Apr. 22, 2014), Device and Method for Derectional Delivery of a Drug Depot. |
| U.S. Appl. No. 12/507,197 (U.S. Pat. No. 8,715,223), filed Jul. 22, 2009 (May 6, 2014), Device and Method for Delivery of a Drug Depot Near the Nerve. |
| U.S. Appl. No. 12/609,937, filed Oct. 30, 2009, Devices and Methods for Implanting a Plurality of Drug Depots Having One or More Anchoring Members. |
| U.S. Appl. No. 12/693,853 (U.S. Pat. No. 8,267,895), filed Jan. 26, 2010 (Sep. 18, 2012), Needle Guide System. |
| U.S. Appl. No. 12/694,329 (U.S. Pat. No. 7,955,301), filed Jan. 27, 2010 (Jun. 7, 2011), Injection Shut Off Valve With Pressure Actuator for Delivery of Compositions. |
| U.S. Appl. No. 12/695,899 (U.S. Pat. No. 8,998,854), filed Jan. 28, 2010 (Apr. 7, 2015), Catheter Devices and Drainage Systems for Delivering Therapeutic Agents. |
| U.S. Appl. No. 11/403,733 (U.S. Pat. No. 7,741,273), filed Apr. 13, 2006 (Jun. 22, 2010), Drug Depot Implant Designs. |
| U.S. Appl. No. 12/715,093 (U.S. Pat. No. 8,481,064), filed Mar. 1, 2010 (Jul. 9, 2013), Method for Delivering a Therapeutic Agent Comprising Injection of Microspheres. |
| U.S. Appl. No. 11/734,618 (U.S. Pat. No. 7,727,954), filed Apr. 12, 2007 (Jun. 1, 2010), Drug Depots Implant Designs. |
| U.S. Appl. No. 12/716,383 (U.S. Pat. No. 8,357,388), filed Mar. 3, 2010 (Jan. 22, 2013), Drug Depot Implant Designs and Methods of Implantation. |
| U.S. Appl. No. 12/861,857 (U.S. Pat. No. 8,246,571), filed Aug. 24, 2010 (Mar. 1, 2012), Drug Storage and Delivery Device Having a Retaining Member. |
| U.S. Appl. No. 13/309,725, filed Dec. 2, 2011, Methods for Delivering Clonidine Compositions in Biodegradable Polymer Carrier and Local Steroids to a Target Tissue Site. |
| U.S. Appl. No. 13/309,759, filed Dec. 2, 2011, Compsitions and Methods for Delivering Clonidine to a Target Tissue Site. |
| U.S. Appl. No. 14/341,026 (U.S. Pat. No. 10,080,877), filed Jul. 25, 2014 (Sep. 25, 2018), Pellet Delivery Device. |
| U.S. Appl. No. 29/569,125 (U.S. Pat. No. D. 809,652), filed Jun. 23, 2016 (Feb. 6, 2018), Pellett Delivery Device. |
| U.S. Appl. No. 14/341,461 (U.S. Pat. No. 9,775,978), filed Jan. 28, 2016 (Oct. 3, 0217), Drug Delivery Device and Methods Having a Retaining Member. |
| U.S. Appl. No. 15/703,512 (U.S. Pat. No. 10,478,603), filed Sep. 13, 2017 (Nov. 19, 2019), Drug Delivery Device and Methods Having a Retaining Member. |
| U.S. Appl. No. 16/686,593, filed Nov. 18, 2019, Drug Delivery Device and Methods Having a Retaining Member. |
| U.S. Appl. No. 14/949,118 (U.S. Pat. No. 10,076,650), filed Nov. 23, 2015 (Sep. 18, 2018), Enhanced Stylet for Drug Depot Injector. |
| U.S. Appl. No. 16/132,808, filed Sep. 17, 2018, Enhanced Stylet for Drug Depot Injector. |
| U.S. Appl. No. 14/341,256 (U.S. Pat. No. 9,764,122), filed Jul. 25, 2014 (Sep. 19, 2017), Drug Delivery Device and Methods Having an Occluding Member. |
| U.S. Appl. No. 15/689,810 (U.S. Pat. No. 10,384,048), filed Aug. 29, 2017 (Aug. 20, 2019), Drug Delivery Device and Methods Having an Occluding Member. |
| U.S. Appl. No. 16/544,064, filed Aug. 19, 2019, Drug Delivery Device and Methods Having an Occluding Member. |
| U.S. Appl. No. 15/190,861 (U.S. Pat. No. 10,549,081), filed Jun. 23, 2016 (Feb. 4, 2020), Drug Delivery Device and Methods Having a Retaining Member. |
| U.S. Appl. No. 16/779,930, filed Feb. 3, 2020, Drug Delivery Device and Methods Having a Retaining Member. |
| U.S. Appl. No. 29/569,092 (U.S. Pat. No. D. 802,755), filed Jun. 23, 2016 (Nov. 14, 2017), Drug Pellet Cartridge. |
| U.S. Appl. No. 29/569,107 (U.S. Pat. No. D. 802,756), filed Jun. 23, 2016 (Nov. 14, 2017), Drug Pellet Cartridge. |
| U.S. Appl. No. 29/569,123 (U.S. Pat. No. D. 802,757), filed Jun. 23, 2016 (Nov. 14, 2017), Drug Pellet Cartridge. |
| U.S. Appl. No. 15/345,764 (U.S. Pat. No. 10,434,261), filed Nov. 8, 2016 (Oct. 8, 2019), Drug Pellet Delivery System and Method. |
| U.S. Appl. No. 16/590,654, filed Oct. 2, 2019, Drug Pellet Delivery System and Method. |
| Abd-Elsayed et al., “A Double-Blind Randomized Controlled Trial Comparing Epidural Clonidine vs Bupivacaine for Pain Control During and After Lower Abdominal Surgery”, The Ochsner Journal, 2015, vol. 15, pp. 133-142. |
| International Search Report and Written Opinion for PCT/US2015/040472, dated Nov. 3, 2015, 14 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20200078576 A1 | Mar 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14341461 | Jul 2014 | US |
| Child | 15703512 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15703512 | Sep 2017 | US |
| Child | 16686593 | US |
